Search Results - "LINN, S. C"

Cox proportional hazards regression in small studies of predictive biomarkers by Jóźwiak, K., Nguyen, V. H., Sollfrank, L., Linn, S. C., Hauptmann, M.

“…Predictive biomarkers are essential for personalized medicine since they select the best treatment for a specific patient. However, of all biomarkers that are…”
Get full text

Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08) by van Roozendaal, L M, Vane, M L G, van Dalen, T, van der Hage, J A, Strobbe, L J A, Boersma, L J, Linn, S C, Lobbes, M B I, Poortmans, P M P, Tjan-Heijnen, V C G, Van de Vijver, K K B T, de Vries, J, Westenberg, A H, Kessels, A G H, de Wilt, J H W, Smidt, M L

“…Studies showed that axillary lymph node dissection can be safely omitted in presence of positive sentinel lymph node(s) in breast cancer patients treated with…”
Get full text

A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer by Sollfrank, L, Linn, S C, Hauptmann, M, Jóźwiak, K

“…Many scientific papers are published each year and substantial resources are spent to develop biomarker-based tests for precision oncology. However, only a…”
Get full text

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study by Drukker, C.A., Bueno‐de‐Mesquita, J.M., Retèl, V.P., Harten, W.H., Tinteren, H., Wesseling, J., Roumen, R.M.H., Knauer, M., Veer, L.J., Sonke, G.S., Rutgers, E.J.T., Vijver, M.J., Linn, S.C.

“…The 70‐gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant…”
Get full text

A real or apparent decrease in glomerular filtration rate in patients using olaparib? by Bruin, M. A. C., Korse, C. M., van Wijnen, B., de Jong, V. M. T., Linn, S. C., van Triest, B., Rosing, H., Beijnen, J. H., van den Broek, D., Huitema, A. D. R.

“…Purpose Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for ovarian and metastatic breast cancer. Increased serum creatinine levels have…”
Get full text

Correction: A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer by Sollfrank, L, Linn, SC, Hauptmann, M, Jóźwiak, K

Get full text

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients by Vollebergh, M.A., Lips, E.H., Nederlof, P.M., Wessels, L.F.A., Schmidt, M.K., van Beers, E.H., Cornelissen, S., Holtkamp, M., Froklage, F.E., de Vries, E.G.E., Schrama, J.G., Wesseling, J., van de Vijver, M.J., van Tinteren, H., de Bruin, M., Hauptmann, M., Rodenhuis, S., Linn, S.C.

“…Breast cancer cells deficient for BRCA1 are hypersensitive to agents inducing DNA double-strand breaks (DSB), such as bifunctional alkylators and platinum…”
Get full text

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature by Opdam, M., van der Noort, V., Kleijn, M., Glas, A., Mandjes, I., Kleiterp, S., Hilbers, F. S., Kruger, D. T., Bins, A. D., de Jong, P. C., Schiphorst, P. P. J. B. M., van Dalen, T., Flameling, B., Rietbroek, R. C., Beeker, A., van den Heiligenberg, S. M., Bakker, S. D., Wymenga, A. N. M., Oving, I. M., Bijlsma, R. M., van Diest, P. J., Vermorken, J. B., van Tinteren, H., Linn, S. C.

“…Purpose Guidelines recommend endocrine treatment for estrogen receptor-positive (ER+) breast cancers for up to 10 years. Earlier data suggest that the 70-gene…”
Get full text

Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in de novo stage IV breast cancer patients: study protocol of the i-GO study by de Maar, Josanne S, Suelmann, Britt B M, Braat, Manon N G J A, van Diest, P J, Vaessen, H H B, Witkamp, Arjen J, Linn, S C, Moonen, Chrit T W, van der Wall, Elsken, Deckers, Roel

“…IntroductionIn breast cancer, local tumour control is thought to be optimised by administering higher local levels of cytotoxic chemotherapy, in particular…”
Get full text

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy by Straver, M. E., Rutgers, E. J. Th, Rodenhuis, S., Linn, S. C., Loo, C. E., Wesseling, J., Russell, N. S., Oldenburg, H. S. A., Antonini, N., Vrancken Peeters, M. T. F. D.

“…Background Breast cancer is increasingly considered a heterogeneous disease. The aim of this study was to assess the differences between histological and…”
Get full text

The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07) by van Roozendaal, L M, de Wilt, J H W, van Dalen, T, van der Hage, J A, Strobbe, L J A, Boersma, L J, Linn, S C, Lobbes, M B I, Poortmans, P M P, Tjan-Heijnen, V C G, Van de Vijver, K K B T, de Vries, J, Westenberg, A H, Kessels, A G H, Smidt, M L

“…Trials failed to demonstrate additional value of completion axillary lymph node dissection in case of limited sentinel lymph node metastases in breast cancer…”
Get full text

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature by Knauer, M, Cardoso, F, Wesseling, J, Bedard, P L, Linn, S C, Rutgers, E J T, van 't Veer, L J

“…Background: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend…”
Get full text

Validation of 70-gene prognosis signature in node-negative breast cancer by Bueno-de-Mesquita, J. M, Linn, S. C, Keijzer, R, Wesseling, J, Nuyten, D. S. A, van Krimpen, C, Meijers, C, de Graaf, P. W, Bos, M. M. E. M, Hart, A. A. M, Rutgers, E. J. T, Peterse, J. L, Halfwerk, H, de Groot, R, Pronk, A, Floore, A. N, Glas, A. M, van't Veer, L. J, van de Vijver, M. J

“…Purpose The 70-gene prognosis signature (van't Veer et al., Nature 415(6871):530-536, 2002) may improve the selection of lymph node-negative breast cancer…”
Get full text

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial by Lam, S.W, de Groot, S.M, Honkoop, A.H, Jager, A, ten Tije, A.J, Bos, M.M.E.M, Linn, S.C, van den Bosch, J, Kroep, J.R, Braun, J.J, van Tinteren, H, Boven, E

“…Abstract Background The addition of bevacizumab to paclitaxel or capecitabine has demonstrated improved progression-free survival (PFS) and objective response…”
Get full text

Prognostic factors for survival in metastatic breast cancer by hormone receptor status by Kwast, A. B. G., Voogd, A. C., Menke-Pluijmers, M. B. E., Linn, S. C., Sonke, G. S., Kiemeney, L. A., Siesling, S.

“…Hormone receptor (HR) status is an important prognostic factor for patients with metastatic breast cancer (MBC) and is also correlated with other prognostic…”
Get full text

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen by Jager, N. G. L., Rosing, H., Linn, S. C., Schellens, J. H. M., Beijnen, J. H.

“…The antiestrogenic effect of tamoxifen is mainly attributable to the active metabolites endoxifen and 4-hydroxytamoxifen. This effect is assumed to be…”
Get full text

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study by Dackus, G.M.H.E., Jóźwiak, K., Sonke, G.S., van der Wall, E., van Diest, P.J., Hauptmann, M., Siesling, S., Linn, S.C.

“…Prior randomised controlled trials on adjuvant hormonal therapy included HER2any patients; however, a differential effect of aromatase inhibitors (AIs) versus…”
Get full text

Prospective cost-effectiveness analysis of genomic profiling in breast cancer by Retèl, V.P, Joore, M.A, Drukker, C.A, Bueno-de-Mesquita, J.M, Knauer, M, van Tinteren, H, Linn, S.C, van Harten, W.H

“…Abstract Background The cost-effectiveness of the 70-gene signature (70-GS) (MammaPrint®) has earlier been estimated using retrospective validation data. Based…”
Get full text

The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment by Bueno-de-Mesquita, J. M., Nuyten, D. S. A., Wesseling, J., van Tinteren, H., Linn, S. C., van de Vijver, M. J.

“…Background: It is well known that there is considerable inter-observer variability in assessment of the pathological parameters that are used to select…”
Get full text

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry by Teunissen, S.F., Rosing, H., Koornstra, R.H.T., Linn, S.C., Schellens, J.H.M., Schinkel, A.H., Beijnen, J.H.

“…The development and validation of a bioanalytical assay is described for the simultaneous analysis in human serum of tamoxifen, four of its main metabolites…”
Get full text